Drug firm Ipca Laboratories today reported a net profit of Rs 75.43 crore for the fourth quarter ended March 31, 2013, on the back of robust sales.
It had posted a net profit of Rs 76.61 crore for the corresponding quarter of the previous fiscal, the company said in a statement.
“Since the entire effect of amalgamation of Tonira Pharma Ltd with the company was given in the last quarter of the financial year ended March 31, 2012, the financial results of quarter ended March 31, 2013 and quarter ended March 31, 2012 are not comparable,” Ipca Laboratories said.
Total income from operations, however, rose to Rs 671.71 crore for the quarter under consideration from Rs 561.83 crore for the same period a year ago.
In a separate filing on the BSE, the company said its board of directors has recommended a final dividend of Rs 2 per share for the financial year ended March 31, 2013.
Net profit for the financial year ended March 31, 2013, rose to Rs 331.39 crore from Rs 280.17 crore for the previous fiscal.
The company’s total income from operations stood at Rs 2,778.42 crore for the fiscal year ended March 31, 2013, against Rs 2,330.06 crore in the previous fiscal.
The company has a strong thrust on exports, which account for 61 per cent of the income, Ipca Laboratories said.
Shares of Ipca Laboratories were trading at Rs 609.55 per scrip in late afternoon, up 3.11 per cent from its previous close on the BSE.